Akira Homma

Summary

Affiliation: Rio de Janeiro
Country: Brazil

Publications

  1. pmc Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline
    Ana Carolina Campi-Azevedo
    Centro de Pesquisas Rene Rachou Fiocruz, Belo Horizonte, Minas Gerais, Brazil
    BMC Infect Dis 14:391. 2014
  2. ncbi request reprint Vaccine research, development, and innovation in Brazil: a translational science perspective
    Akira Homma
    Bio Manguinhos, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
    Vaccine 31:B54-60. 2013
  3. ncbi request reprint The Brazilian vaccine manufacturers' perspective and its current status
    Akira Homma
    Bio Manguinhos Fiocruz, Pavilhão Rocha Lima, Manguinhos, Rio de Janeiro, Brasil
    Biologicals 37:173-6. 2009
  4. ncbi request reprint [Vaccines, immunization and technological innovation: an update]
    Akira Homma
    Instituto de Tecnologia em Imunobiológicos de Bio Manguinhos, Rio de Janeiro RJ
    Cien Saude Colet 16:445-58. 2011
  5. ncbi request reprint Immunogenicity, reactogenicity and consistency of production of a Brazilian combined vaccine against diphtheria, tetanus, pertussis and Haemophilus influenzae type b
    Reinaldo de Menezes Martins
    Assessoria Clínica, Rio de Janeiro, RJ, Brasil
    Mem Inst Oswaldo Cruz 103:711-8. 2008
  6. ncbi request reprint Study of the genetic stability of measles virus CAM-70 vaccine strain after serial passages in chicken embryo fibroblasts primary cultures
    Maria Beatriz Borges
    Bio Manguinhos, Fundação Oswaldo Cruz, Av Brasil, 4365 Manguinhos, Rio de Janeiro, RJ 21040 360, Brazil
    Virus Genes 36:35-44. 2008
  7. ncbi request reprint Incidence of hypotonic-hyporesponsive episodes associated to the combined DTP/Hib vaccine used in Brazilian National Immunizations Program
    Reinaldo M Martins
    Fundação Oswaldo Cruz FIOCRUZ, Rio de Janeiro, RJ, Brazil
    J Pediatr (Rio J) 83:523-8. 2007
  8. pmc 17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study
    Reinaldo M Martins
    Bio Manguinhos, Fiocruz Rio de Janeiro, Brazil
    Hum Vaccin Immunother 9:879-88. 2013

Collaborators

  • Luiz Antonio Bastos Camacho
  • Reinaldo Menezes Martins
  • Ana Carolina Campi-Azevedo
  • Ricardo Galler
  • Maria Beatriz Borges
  • Gloria Regina Silva Sá
  • Gabriela Villela-Rezende
  • Olindo Assis Martins-Filho
  • Paula de Almeida Estevam
  • Luiz Fernando Carvalho Almeida
  • Darcy Akemi Hokama
  • Ricardo de Carvalho
  • Sheila Maria Barbosa Lima
  • Roberto Henrique Guedes Farias
  • Marcos da Silva Freire
  • Andréa Teixeira-Carvalho
  • Vanessa Peruhype-Magalhães
  • Maria da Luz Fernandes Leal
  • Maria de Lourdes Sousa Maia
  • Edson Pereira Filho
  • Anna Maya Yoshida Yamamura
  • Rita Maria Ribeiro Nogueira
  • Jordana Grazziela Coelho-Dos-Reis
  • Ricardo Aguiar Villanova Freire
  • Patrícia Flávia Quaresma
  • José Marcus N Malachias
  • Elena Caride
  • Marcos S Freire
  • Alfredo V Jabor

Detail Information

Publications8

  1. pmc Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline
    Ana Carolina Campi-Azevedo
    Centro de Pesquisas Rene Rachou Fiocruz, Belo Horizonte, Minas Gerais, Brazil
    BMC Infect Dis 14:391. 2014
    ..The present work aimed at comparing the serum chemokine and cytokine kinetics triggered by five subdoses of 17DD YF Vaccine...
  2. ncbi request reprint Vaccine research, development, and innovation in Brazil: a translational science perspective
    Akira Homma
    Bio Manguinhos, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
    Vaccine 31:B54-60. 2013
    ..We also discuss the lessons learned from the Brazilian experience in the implementation of governmental policies on vaccine innovation that could be applicable to other developing countries...
  3. ncbi request reprint The Brazilian vaccine manufacturers' perspective and its current status
    Akira Homma
    Bio Manguinhos Fiocruz, Pavilhão Rocha Lima, Manguinhos, Rio de Janeiro, Brasil
    Biologicals 37:173-6. 2009
    ....
  4. ncbi request reprint [Vaccines, immunization and technological innovation: an update]
    Akira Homma
    Instituto de Tecnologia em Imunobiológicos de Bio Manguinhos, Rio de Janeiro RJ
    Cien Saude Colet 16:445-58. 2011
    ..Brazil has also established a new innovation policy, creating new laws as well as subsidizing projects in technological innovation and modernization of production infra-structure...
  5. ncbi request reprint Immunogenicity, reactogenicity and consistency of production of a Brazilian combined vaccine against diphtheria, tetanus, pertussis and Haemophilus influenzae type b
    Reinaldo de Menezes Martins
    Assessoria Clínica, Rio de Janeiro, RJ, Brasil
    Mem Inst Oswaldo Cruz 103:711-8. 2008
    ..Adverse events rates were comparable among the vaccine groups. The Brazilian DTP/Hib vaccine demonstrated an immunogenicity and reactogenicity profile similar to that of the reference vaccine...
  6. ncbi request reprint Study of the genetic stability of measles virus CAM-70 vaccine strain after serial passages in chicken embryo fibroblasts primary cultures
    Maria Beatriz Borges
    Bio Manguinhos, Fundação Oswaldo Cruz, Av Brasil, 4365 Manguinhos, Rio de Janeiro, RJ 21040 360, Brazil
    Virus Genes 36:35-44. 2008
    ..This study shows that the measles CAM-70 vaccine virus is highly adapted to its cultivation conditions and that its genetic stability contributes, in part, to the safety profile of the vaccine...
  7. ncbi request reprint Incidence of hypotonic-hyporesponsive episodes associated to the combined DTP/Hib vaccine used in Brazilian National Immunizations Program
    Reinaldo M Martins
    Fundação Oswaldo Cruz FIOCRUZ, Rio de Janeiro, RJ, Brazil
    J Pediatr (Rio J) 83:523-8. 2007
    ..To evaluate the safety of a combined diphtheria-tetanus-whole cell pertussis-Haemophilus influenzae type b vaccine used on the Brazilian National Immunizations Program, chiefly the incidence of hypotonic-hyporesponsive episodes...
  8. pmc 17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study
    Reinaldo M Martins
    Bio Manguinhos, Fiocruz Rio de Janeiro, Brazil
    Hum Vaccin Immunother 9:879-88. 2013
    ..To verify if the Bio-Manguinhos 17DD yellow fever vaccine (17DD-YFV) used in lower doses is as immunogenic and safe as the current formulation...